BlueCrest Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,000
| Closed | -$304K | – | 221 |
|
|
2023
Q1 | $304K | Buy |
+3,000
| New | +$304K | 0.01% | 174 |
|
|
2019
Q4 | – | Sell |
-3,895
| Closed | -$351K | – | 494 |
|
|
2019
Q3 | $351K | Buy |
+3,895
| New | +$351K | 0.02% | 319 |
|
|
2018
Q4 | – | Sell |
-21,468
| Closed | -$2.64M | – | 1210 |
|
|
2018
Q3 | $2.64M | Buy |
+21,468
| New | +$2.64M | 0.07% | 189 |
|
|
2018
Q1 | – | Sell |
-17,176
| Closed | -$1.33M | – | 1563 |
|
|
2017
Q4 | $1.33M | Sell |
17,176
-8,005
| -32% | -$621K | 0.04% | 326 |
|
|
2017
Q3 | $1.54M | Buy |
25,181
+13,081
| +108% | +$802K | 0.06% | 274 |
|
|
2017
Q2 | $557K | Buy |
+12,100
| New | +$557K | 0.02% | 551 |
|
|
2016
Q4 | – | Sell |
-4,529
| Closed | -$229K | – | 762 |
|
|
2016
Q3 | $229K | Sell |
4,529
-3,044
| -40% | -$154K | 0.01% | 608 |
|
|
2016
Q2 | $344K | Sell |
7,573
-15,462
| -67% | -$702K | 0.01% | 612 |
|
|
2016
Q1 | $911K | Buy |
+23,035
| New | +$911K | 0.06% | 357 |
|